Here are relevant reports on : gene-therapy-market
-
Glioblastoma Multiforme Drug Market by Therapy (Chemotherapy, Immunotherapy), Drug Class, End Use, Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast to 2027
The global glioblastoma multiforme drug market is projected to reach USD ~880 million by 2027 from USD 600 million in 2022, at a CAGR of 8% during the forecast period
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Biopharmaceutical Contract Manufacturing Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030
The global biopharmaceutical contract manufacturing market, valued at US$20.51 billion in 2024, stood at US$22.40 billion in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2025 to 2030, culminating in a forecasted valuation of US$34.15 billion by the end of the period. The growth is primarily driven by the rising demand for outsourcing services and an increasing need for biologics and biosimilars. However, challenges related to intellectual property rights are anticipated to pose barriers to market growth.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Biophotonics Market by Application(See-through Imaging, Inside Imaging, Spectromolecular, Surface Imaging, Microscopy, Light Therapy, Biosensors), Technology(In-vivo, In-vitro), End-use(Diagnostics, Therapeutic, Tests), & Geography - Global Forecast to 2020
The overall market for biophotonics in 2014 was valued at USD 26.26 Billion, which is estimated to reach USD 50.18 Billion by 2020, at a CAGR of 11.5% during the forecast period. This market growth can be attributed to emergence of nanotechnology, significant technological advancements over the last few years and their adoption in the medical sector, increase in the demand for home-based POC devices, aging population, and growing lifestyle diseases.
- Published: November 2015
- Price: $ 4950
- TOC Available:
-
Autoinjectors Market by Type (Devices, Finished Formulation), Usage (Disposable, Reusable), Actuation Mechanism (Mechanical, Electronic), Therapy (Rheumatoid Arthritis, Obesity, Diabetes), ROA (SC, IM), Volume (< 3ml, > 3ml) - Global Forecast to 2031
The global autoinjectors market, valued at USD 107.60 billion in 2025, stood at USD 127.30 billion in 2026 and is projected to advance at a resilient CAGR of 18.7% from 2026 to 2031, culminating in a forecasted valuation of USD 300.46 billion by the end of the period. Some of the leading companies in the device-only autoinjectors market include Becton, Dickinson and Company (US), SHL Medical (Switzerland), and Ypsomed (Switzerland). Key players in the finished formulation autoinjectors market include Novo Nordisk (Denmark), AbbVie Inc. (US), and Eli Lilly and Company (US).
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Digital Therapeutics Market / DTx Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) - Global Forecast to 2028
The global digital therapeutics market, valued at US$4.4 billion in 2022, stood at US$6.1 billion in 2023 and is projected to advance at a resilient CAGR of 29.1% from 2023 to 2028, culminating in a forecasted valuation of US$21.9 billion by the end of the period. The rapid adoption of digital therapeutics is driven by the rising incidence of chronic diseases, surging investments from venture capital firms, and strategic partnerships between tech companies and healthcare providers.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Patient Engagement Solutions Market by Component (Software (Pre-Care, Post-Care)) Therapy (CVD, Diabetes, Obesity, Fitness), Function (Telehealth, ePrescribing, Scheduling, Billing), Delivery, End User (Hospital, Payer, Patient) - Global Forecast to 2031
The global patient engagement solutions market is projected to reach USD 54.16 billion by 2031, growing at a CAGR of 12.2% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Wearables in Pharma & Biotech Market by Product (Smartwatches, CGMs, Bands, Rings, Patches, Injectors), Therapy (Diabetes, Cardio, Onco, Mental Health), Application (Drug Discovery, Clinical Trials, Medication Adherence), End User - Global Forecasts to 2031
The global wearables in pharma & biotech market is projected to reach USD 9.97 billion by 2031, growing at a CAGR of 20.2% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Patient Engagement Solutions Market by Therapy (Chronic [Obesity, Diabetes], Women’s Health), Functionality (Telehealth, E-Prescribing, Scheduling, Billing), End User (Hospital, ASC, Payer, Patient), Unmet Need, Investment - Forecast to 2030
The Asia Pacific Patient Engagement Solutions market, valued at USD 3.45 billion in 2024, stood at USD 3.97 billion in 2025 and is projected to advance at a resilient CAGR of 13.5% from 2025 to 2030, culminating in a forecasted valuation of USD 7.48 billion by the end of the period. This growth is driven by the rising demand for patient-centered and personalized care, a rapid expansion of telehealth and remote care frameworks, and more investments in digital healthcare infrastructure within the Asia Pacific region.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
The global monoclonal antibody therapeutics market, valued at US$222.6 billion in 2023, stood at US$252.6 billion in 2024 and is projected to advance at a resilient CAGR of 14.5% from 2024 to 2029, culminating in a forecasted valuation of US$497.5 billion by the end of the period. Driving factors of the market, including clinical trials, encompass increasing prevalence of complex diseases, advancements in biotechnology facilitating targeted treatments, regulatory support expediting approval processes, and robust investments in research and development.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Oxygen Therapy Equipment Market by Product (Oxygen Source (Concentrator, Cylinder), Delivery Devices), Portability (Stationary, Portable), Application (COPD, Asthma, Cystic Fibrosis, Pneumonia), End User (Hospital, Home Care) - Global Forecast to 2022
The oxygen therapy equipment market is expected to reach USD 4.01 Billion by 2022 from USD 2.65 Billion in 2017, at a CAGR of 8.7% from 2017 to 2022. Factors driving the growth of this market are the increasing prevalence of respiratory disorders, rapid growth in the geriatric population, prevalence of tobacco smoking, preference towards home-based oxygen therapy, and technological advancements to develop novel products delivering oxygen therapy.
- Published: May 2017
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
